Cooperative Agreement UG3AG098023
Award Date 2/15/26
Completion Date 3/15/28
Dollars Obligated $2.6M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
San Ramon, CA 94583, USA
Similar Awards
- Federal Grant Award Summary Artery Therapeutics, Inc. received a $2.45 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) to manufacture approximately 2.3 kilograms of Good Manufacturing Practices (GMP)-grade CS6253, an ABCA1 agonist small molecule peptide. The manufacturing services, to be provided by subcontractor Ambiopharm, Inc., a contract development and manufacturing organization (CDMO), will produce the drug substance required to...
- Cooperative Agreement Summary The National Institute on Aging awarded the University of Southern California a Cooperative Agreement valued at $1,480,275 under the Aging Research program (CFDA 93.866) to support drug development targeting neuroinflammation in Alzheimer's disease (AD). The award, effective August 1, 2025 through July 31, 2030, funds research focused on calcium-dependent phospholipase A2 (cPLA2) inhibition as a therapeutic approach. USC will establish comprehensive...
- Cooperative Agreement Award Summary The University of California, San Diego received a $3.2M Cooperative Agreement from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded August 15, 2025, with a completion date of July 31, 2027. The award funds in vitro pharmacology, chronic toxicology, and embryo-fetal development studies to demonstrate the safety profile of GSM-779690, a small-molecule g-secretase modulator (GSM) candidate therapeutic. These preclinical...
- Federal Cooperative Agreement Summary New York University School of Medicine received a $3.31 million Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective June 4, 2025 through May 31, 2027. The award funds research to characterize the vascular pathophysiology underlying amyloid-related imaging abnormalities (ARIA) that develop...
- Federal Project Grant Award Summary Advantage Therapeutics, Inc. received a $1,249,957 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective September 20, 2025, with a completion date of May 31, 2027. The award funds preclinical and Investigational New Drug (IND)-enabling studies for a small-molecule disease-modifying therapeutic targeting Alzheimer's disease. The compound under development is designed to reduce brain inflammation and...
- Federal Cooperative Agreement Summary The University of Alabama at Birmingham received a $2.8M cooperative agreement from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) effective September 1, 2025 through August 31, 2028. This award supports fundamental research investigating how accelerated aging in the Low Earth Orbit (LEO) environment can elucidate pathogenic mechanisms and potential treatments for Alzheimer's disease and progressive neurological...
- Federal Cooperative Agreement Summary Vanderbilt University Medical Center received a $1,013,072 Cooperative Agreement from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded September 1, 2025, with completion targeted for August 31, 2027. The award supports a two-phase drug discovery initiative leveraging single-cell foundation models, human genetics, and electronic health records (EHR) to identify therapeutics targeting clonal hematopoiesis of...
- Federal Cooperative Agreement Summary The National Institute on Aging (Aging Research program, CFDA 93.866) awarded a $5.17 million Cooperative Agreement to Biosensics LLC, effective September 1, 2025, through August 31, 2029. The award supports development and qualification of digital health monitoring biomarkers for Progressive Supranuclear Palsy (PSP) and Dementia with Lewy Bodies (DLB), two neurodegenerative diseases with significant motor impairment but no FDA-approved treatments....
- Federal Cooperative Agreement Award Summary Cedars-Sinai Medical Center received a $2.25 million Cooperative Agreement from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 15, 2025, with a completion date of August 31, 2030. Under the Microvascular Aging Effects – Women's Evaluation of Systemic Aging Tenacity in Heart, Brain and Frailty (MAE-WEST HBF) Specialized Center of Research Excellence (SCORE) initiative, Principal Investigator C....
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $6.47 million R01 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded September 1, 2025, with a completion date of August 31, 2030. The award funds continued implementation of the Ante-Amyloid Treatment of Alzheimer's Disease (A3) Trial and the Alzheimer Plasma Extension (APEX) Study, which are components of the larger AHEAD 3-45 research initiative. These...